Dr. Iacone is a physician-scientist with more than 15 years of experience in the life science industry. Before Alentis he was Global Head of Rare…
Sina Kohlbrenner19.08.2020
The orphan drug designation can only be granted for treatments on rare diseases to advance the developments of safe and effective therapies and the FDA…
Sina Kohlbrenner19.08.2020
PharmaBiome also welcomed two new board members with extensive biotech and entrepreneurial experience, all the way from founding to IPO. Dr. Thomas Meier joins PharmaBiome…
Sina Kohlbrenner19.08.2020
T3 Pharmaceuticals (T3 Pharma) has successfully closed a third financing round, raising over 25 million Swiss francs. According to a press release, the financing was co-led…
Emma Bulmer27.07.2020
We are proud to announce that BB Pureos Bioventures has become a partner in BaseLaunch Phase II as the first venture capital fund. Anja Harmeier,…
Jérémie Meyer08.06.2020
Congratulations to one of BaseLaunch’s portfolio companies, Polyneuron on their latest milestone: First clinical trial application approval. Wishing you great success with the studies later…
Jérémie Meyer11.05.2020
Anaveon, a Basel-based immuno-oncology biotech, has successfully concluded a Series A financing round led by Syncona, a UK Life Sciences fund, and joined by the…
Jérémie Meyer05.03.2020
Polyneuron Pharmaceuticals, one of our portfolio companies has successfully raised 22.5 million francs in a round of financing. The Basel-based company will use the proceeds…
Jérémie Meyer04.03.2020
The Basel-based biotech company Alentis Therapeutics AG has successfully concluded a CHF 12.5 million Series A financing co-lead by BioMedPartners and BB Pureos Bioventures and joined by…
Jérémie Meyer03.03.2020
